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Essentials
• The C-terminus of tissue factor pathway inhibitor (TFPIa) binds to the B-domain of factor V (FV).
• The functional consequences of this interaction were investigated in plasma and model systems.
• The TFPIa C-terminus inhibited thrombin generation in plasma, but not in the presence of FVa.
• The TFPIa C-terminus inhibited FV activation by preventing cleavage at Arg 1545 .
Summary. Background: Factor V (FV) is a carrier and a cofactor of the anticoagulant protein tissue factor pathway inhibitor-a (TFPIa), whose basic C-terminus binds to an acidic region in the B-domain of FV. Proteolysis of FV at Arg 709 , Arg 1018 and Arg 1545 by activated FX (FXa) or thrombin removes the B-domain, and converts FV into a procoagulant cofactor (activated FV [FVa] ) of FXa in the prothrombinase complex. However, retention of the acidic region in partially activated FV makes prothrombinase activity susceptible to inhibition by TFPIa. Objective/Methods: To investigate the effect of the TFPIa C-terminal peptide (TFPIa C-term) on thrombin generation in plasma and on FV activation in model systems. Results: TFPIa C-term inhibited tissue factorinitiated and FXa-initiated thrombin generation in a dose-dependent manner. Failure to inhibit thrombin generation in FV-depleted plasma reconstituted with FVa indicated that the peptide effect was mediated by the acidic region of FV, and was localized at the level of FV activation and/or prothrombinase. In model systems, TFPIa C-term inhibited both FV activation and prothrombinase activity. Western blot analysis showed that the peptide impaired cleavage at Arg 1545 by both thrombin and FXa. The inhibition was stronger for FVshort, which binds TFPIa with higher affinity. Similar results were obtained with full-length TFPIa. Conclusions: Cleavage of FV at Arg
Introduction
Coagulation factor V (reviewed in [1] ) is a 330-kDa multidomain (A1-A2-B-A3-C1-C2) glycoprotein that circulates in plasma as an inactive procofactor. The inactive state is maintained by a high-affinity interaction (K d~2 nM) between evolutionarily conserved basic and acidic regions (residues 963-1008 and 1493-1537, respectively) in the B-domain [2] [3] [4] . Limited proteolysis of FV by activated FX (FXa) [5, 6] or thrombin [7, 8] releases the B-domain, and generates activated FV (FVa), which consists of a heavy chain (A1-A2) and a light chain (A3-C1-C2) held together by a Ca 2+ ion. FVa binds to FXa on negatively charged phospholipids to form the prothrombinase complex, accelerating prothrombin activation by several orders of magnitude [9] .
Both FXa and thrombin cleave FV at Arg 709 , Arg 1018 , and Arg 1545 [6, 8] . These proteolytic events disrupt the interaction between the basic and acidic regions [4] , and progressively expose the FXa-binding site [10] . Cleavage at Arg 709 and Arg
1018
, which are the kinetically favored sites, removes the basic region, yielding an intermediate with considerable FXa-cofactor activity. However, full FV activation requires cleavage at Arg 1545 [7] , which is proteolysed more efficiently by thrombin than by FXa [5] . An additional FXa-cleavage site has been identified at Arg 1765 in the light chain [6] .
FV also acts as a carrier of plasma full-length tissue factor (TF) pathway inhibitor-a (TFPIa) [11] , a multivalent Kunitz-type protease inhibitor that inhibits the TF-activated FVII (FVIIa) complex and FXa (reviewed in [12] ). The interaction with FV is mediated by the TFPIa C-terminus [13] , which is strikingly homologous to the basic region of FV, and can therefore bind to the acidic region of FV [13, 14] . Recent studies in model systems have elucidated two important functional implications of the FV-TFPIa interaction. First, it has been observed that TFPIa inhibits prothrombinase complexes containing forms of FVa that retain the acidic region [14] . Moreover, it has been shown that FV stimulates the inhibition of FXa by TFPIa, most likely by promoting TFPIa binding to phospholipids [15] . These anticoagulant effects are abolished by cleavage of FV at Arg 1545 , which separates the acidic region of the Bdomain from the light chain of FVa.
Recently, it has also been reported that FV has a minor splicing isoform that lacks most of the B-domain, including the basic region [16] . This so-called FV-short isoform binds TFPIa with much higher affinity than FV, because its acidic region is free to interact with the C-terminus of TFPIa. Accordingly, it has been estimated that, although FV-short represents only~5% of all plasma FV, plasma TFPIa is equally distributed between FV and FV-short. An excess of FV-short is associated with increased plasma TFPIa levels and a moderate bleeding tendency (East Texas bleeding disorder) [16] .
To obtain more insights into the functional significance of the FV-TFPIa interaction, we have studied the effect of a peptide with the same sequence as the C-terminus of TFPIa on thrombin generation in plasma and on FV activation in model systems. The most important findings were also validated with full-length TFPIa.
Materials and methods

TFPIa C-terminal peptide
A peptide (TFPIa C-term) with the same amino acid sequence as the C-terminus of human TFPIa (NAc-GFIQRISKGGLIKIKRKRKKQRVKIAYEEIFVKNM-COOH, residues 242-276 of the mature protein) was made by solid-phase peptide synthesis and purified by HPLC, as described previously [17] . Control experiments with small chromogenic/fluorogenic substrates indicated that this arginine-rich peptide does not act as an alternative substrate for FXa or thrombin.
Plasma samples for thrombin generation
Normal pooled plasma was prepared by pooling citrated plasma from 23 healthy volunteers (13 males and 10 females; mean age 34.7 years), as described previously [18] .
FV-depleted plasma (Siemens Healthcare, Marburg, Germany) was reconstituted with 2.5 nM purified FV or FVa (Haematologic Technologies, Essex Junction, VT, USA), and supplemented with 0.25 nM full-length TFPIa (kindly provided by T. Lindhout, Maastricht University) to compensate for the low level of TFPIa in FV-depleted plasma [11] .
Thrombin generation
Thrombin generation was measured in normal pooled plasma or reconstituted FV-depleted plasma by calibrated automated thrombography [19] . Plasma was preincubated with 40 lg mL À1 thermostable inhibitor of contact activation (synthesized in-house) [20] 
Expression of recombinant FV and FV-short
Recombinant FV was expressed using the wild-type pMT2/FV construct [21] . A construct for the expression of recombinant FV-short was prepared by removing nucleotides 2441-4546 (encoding amino acids 756-1458) as described by Vincent et al. [16] . COS-1 cells were grown to 80-90% confluence in Dulbecco's modified Eagle's medium (Lonza, Basel, Switzerland) supplemented with 100 U mL À1 penicillin and 100 lg mL À1 streptomycin, 10% fetal bovine serum, and 2 mM L-glutamine. The medium was then changed to OptiMEM (ThermoFisher, Waltham, MA, USA), and the cells were transiently transfected with the pMT2/FV or pMT2/FVshort construct using Lipofectamine 2000 (Invitrogen, Bleiswijk, the Netherlands), according to the manufacturer's instructions. After 48 h, conditioned media were harvested and centrifuged at 1000 9 g for 10 min to pellet cell debris. The supernatants were concentrated using Amicon Ultra Centrifugal Filter Units with a 100-kDa cut-off (Merck Millipore, Cork, Ireland), snap-frozen, and stored at À 80°C. The FV concentration in the media was determined with a prothrombinase-based activity assay [11] . ). Phospholipid vesicles (40 lM DOPS/DOPC, 10/90, mol/mol) and TFPIa C-term (0-5 lM) were added to the FV dilution, which was prewarmed at 37°C for 5 min. FV activation was started by the addition of 2.5 nM human thrombin (Haematologic Technologies) or 2.5 nM bovine FXa (purified in-house).
In the experiments with recombinant FV, TFPIa C-term was not added to the FV dilution, but premixed with the thrombin used for activation. Timed aliquots were taken from the activation mixture, diluted 10-fold in HNBSA buffer containing 30 mM Ca 2+ and 1 lM Pefabloc TH (Pentapharm, Basel, Switzerland), and transferred to a prothrombinase mixture containing 40 lM phospholipid vesicles (DOPS/DOPC, 10/90, mol/mol), 30 pM FXa, 1 lM prothrombin (Haematologic Technologies) and 1 lM Pefabloc TH (final concentrations) in HNBSA (3 mM Ca 2+ was carried over from the dilution mixture). Prothrombin activation was stopped after 1 min by subsampling to ice-cold EDTA buffer (50 mM Tris, pH 7.9 at room temperature, 175 mM NaCl, 20 mM EDTA, and 0.5 mg mL À1 ovalbumin), and the amount of thrombin formed was quantified with chromogenic substrate S2238 (Pepscan, Lelystad, the Netherlands). The total FV(a) dilution from the activation mixture to the prothrombinase assay was ≥ 100-fold. Control experiments with preactivated FVa indicated that the TFPIa C-term carried over to the prothrombinase mixture did not affect prothrombinase activity under our assay conditions. The activation of purified plasma FV or recombinant FV (2.5 nM) by thrombin (2.5 nM) was also followed in the absence and presence of full-length TFPIa (10 nM). To correct for the inhibition of prothrombinase activity by the TFPIa carried over from the activation mixture, the buffer used to dilute the FV(a) subsamples taken from the activation mixtures without TFPIa was supplemented with TFPIa, resulting in equal TFPIa carry-over to the prothrombinase mixture. In addition, the prothrombinase assay was performed at 300 pM FXa.
Western blot analysis of FV activation
Purified plasma FV (2.5 nM) was activated with 2.5 nM thrombin or FXa in HNBSA/Ca 2+ and 40 lM phospholipid vesicles (DOPS/DOPC, 10/90, mol/mol) in the absence or presence of 5 lM TFPIa C-term or 10 nM TFPIa. At set time-points, samples were taken in nonreducing sample buffer (40 mM Tris, pH 6.7, 50% glycerol, and 3.3% SDS), denatured at 96°C for 5 min, and electrophoresed on polyacrylamide gels in Laemmli running buffer (0.025 M Tris, 0.192 M glycine, and 0.1% SDS) together with an unstained Precision Plus Protein standard (Bio-Rad, Veenendaal, the Netherlands). After the proteins had been transferred to poly vinylidene difluoride membranes by semi-dry blotting, bands were visualized using a mouse mAb directed against the light chain of human FV (AHV-5112; Haematologic Technologies) and a secondary horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (Dako, Glostrup, Denmark). Western blots were developed with WesternBright ECL HRP substrate (Advansta, Menlo Park, CA, USA), and scanned with an ImageQuant LAS 4000 (GE Healthcare Life Sciences, Eindhoven, the Netherlands).
Results
Effect of TFPIa C-term on thrombin generation
TFPIa C-term inhibited thrombin generation in normal plasma in a dose-dependent manner. At a low TF concentration (2 pM), the lag time was prolonged from 3 min in the absence of peptide to 8 min in the presence of 5 lM peptide, whereas the thrombin peak height decreased from 68 nM to 13 nM (Fig. 1A) . The IC 50 of the peptide was~2.5 lM on peak height and~5 lM on the endogenous thrombin potential (ETP). At a higher TF concentration (10 pM), the effect on the lag time was less pronounced and the effect on the peak height was almost completely abolished (Fig. 1B) .
To investigate whether the effect of TFPIa C-term was mediated by plasma TFPI, thrombin generation at 2 pM TF was also measured in the absence and presence of inhibitory anti-TFPI antibodies (which were not directed against the C-terminus of TFPIa, in order not to interfere with TFPIa C-term). In the absence of anti-TFPI antibodies, TFPIa C-term prolonged the lag time and decreased the peak height of thrombin generation ( Fig. 2A) , as also shown in Fig. 1A . In the presence of anti-TFPI antibodies, the inhibitory effect was largely abolished, except for a two-fold prolongation of the lag time (Fig. 2B) . As failure of the peptide to decrease thrombin generation in the presence of anti-TFPI antibodies could be simply attributable to the enhanced thrombin generation associated with TFPI inhibition, the effect of the peptide on thrombin generation in the presence of anti-TFPI antibodies was tested at a lower TF concentration (0.25 pM), chosen to yield a similar thrombin peak as observed at 2 pM TF in the absence of anti-TFPI antibodies. Also under these conditions the peptide affected only the lag time of thrombin generation, causing a similar prolongation of the lag time as was observed at 2 pM TF in the absence of anti-TFPI (Fig. 2C) .
To further localize the effect of TFPIa C-term in the coagulation cascade, thrombin generation was initiated with FXa instead of TF. The concentration of FXa (225 pM) used to initiate thrombin generation was chosen to yield a similar peak height as with 2 pM TF. Also under these conditions the peptide inhibited thrombin generation in a dose-dependent manner, progressively prolonging the lag time and decreasing the peak height of thrombin generation (Fig. 3A) . The observed effects were even more pronounced than with TF-triggered thrombin generation (the IC 50 of the peptide was~0.25 lM on peak height and~1 lM on the ETP), and persisted in the presence of anti-TFPI antibodies (Fig. 3B) .
The fact that TFPIa C-term inhibits thrombin generation triggered with FXa indicated that the peptide acts downstream of FXa, i.e. at the level of FV activation and/or prothrombinase activity. As the TFPI C-terminus is known to interact with the acidic region of FV [11, 13] , we tested the effect of TFPIa C-term on thrombin generation in FV-depleted plasma reconstituted with purified FV or thrombin-activated FVa, which lacks the whole B-domain, including the acidic region. The TFPI level, which is typically low in FV-depleted plasma [11] , was normalized by supplementing with 0.25 nM TFPIa. The peptide potently inhibited thrombin formation in the presence of FV (Fig. 4A) , but not at all in the presence of FVa (Fig. 4B) , suggesting that the inhibitory action of the peptide is indeed mediated by its interaction with the acidic region of FV, and is not attributable to non-specific effects on other coagulation factors. Control experiments also showed that TFPIa C-term up to a concentration of 5 lM did not directly inhibit FXa or thrombin activity (data not shown).
Effect of TFPIa C-term on FV activation
The failure of TFPIa C-term to inhibit thrombin generation in the presence of FVa suggested that the peptide interferes with FV activation and/or with prothrombinase activity supported by partially activated FV species. To test the effect of TFPIa C-term on FV activation, we incubated purified FV with thrombin or FXa in the presence of increasing concentrations of peptide, and followed the generation of FVa activity over time by subsampling to a prothrombinase assay (Fig. 5) . In the absence of peptide, FV activation by thrombin was faster than FV activation by FXa and reached a higher plateau of FVa activity, possibly because of more efficient cleavage of FV at Arg 1545 [5] . Inclusion of TFPIa C-term in the activation mixture decreased FV activation/activity in a dosedependent manner, both with thrombin ( Fig. 5A ) and with FXa (Fig. 5B) . This effect could be attributable to inhibition of the proteolytic activation of FV or to the previously reported inhibition of prothombinase assembled with partially activated FV(a) [14] , or both. To investigate whether TFPIa C-term affects FV proteolysis, the time-courses of thrombin-catalyzed and FXa-catalyzed FV activation in the absence and presence of TFPIa C-term were also followed by western blotting, in order to monitor the peptide bond cleavage pattern during FV activation (Fig. 6 ). This experiment confirmed that cleavage at Arg 1545 , which generates the light chain of FVa, occurs more efficiently in the presence of thrombin than in the presence of FXa. Moreover, it showed that TFPIa C-term inhibits FV proteolysis by both thrombin and FXa, leading to prolonged persistence of the FV 1018-2196 activation intermediate (Fig. 6A) and/or delayed appearance of the light chain band (FV 1545-2196 ) (Fig. 6A,B) . These findings are consistent with the peptide inhibiting cleavage of FV at Arg 1545 .
Effect of TFPIa on FV activation by thrombin
To verify whether full-length TFPIa also inhibits FV activation by thrombin, the time-course of FV activation was followed in the absence and presence of 10 nM TFPIa. As shown in Fig. 7 , TFPIa also inhibited thrombin-mediated cleavage of FV at Arg 1545 as assessed by western blotting (Fig. 7A) , and shifted the t 1/2 of FV activation by approximately 4-fold as determined by a prothrombinasebased FVa assay (Fig. 7B) .
Effect of TFPIa C-term and TFPIa on the activation of FV-short
As FV-short has higher affinity than full-length FV for the C-terminus of TFPIa [16] , we hypothesized that TFPIa Cterm would inhibit the activation of FV-short more strongly than the activation of FV. To test this hypothesis, recombinant FV and FV-short were activated with 2.5 nM thrombin in the absence and presence of 1 lM peptide (Fig. 8A,B) . As FV-short showed partial (~30%) constitutive activity before proteolytic activation, the FVa activity data were corrected for the respective 0-point and expressed as percentage of the final plateau, in order to facilitate comparison between FV and FV-short. Although FV-short was activated by thrombin more rapidly than FV, TFPIa C-term inhibited the activation of FV-short more potently than the activation of FV, 1 lM peptide increasing the t 1/2 of FV activation by~3.5-fold for FV (Fig. 8A) and~10-fold for FV-short (Fig. 8B) .
The activation of recombinant FV and FV-short by thrombin was also followed in the absence and presence of 10 nM full-length TFPIa (Fig. 8C,D) . Although TFPIa hardly affected the activation of FV (Fig. 8C) , it shifted the t 1/2 of FV-short activation by approximately 2-fold (Fig. 8D) , confirming a more pronounced effect on FVshort than on FV.
Comparison of Figs 5A and 8A, and of Figs 7B and 8C, shows that the effects of TFPIa C-term and full-length TFPIa on FV activation/activity were more pronounced for purified plasma FV than for recombinant FV. Control experiments showed that this was attributable in part (< 20%) to the cell medium present in the recombinant FV preparations (data not shown), the rest being probably attributable to intrinsic differences between recombinant FV and plasma-derived FV. Owing to the presence of cell medium, the effects of TFPIa (C-terminus) on the activation of FV and FV-short shown in Fig. 8 are likely to be underestimated, and should be interpreted with caution.
Discussion
The discoveries that the C-terminus of TFPIa binds to the acidic region of the B-domain of FV [4, 14, 22] and that a large fraction of plasma TFPIa actually circulates in complex with FV [11] have raised new questions about the functional significance of the interaction between TFPIa and FV [23] . Studies in model systems have shown that TFPIa inhibits prothrombinase complexes containing forms of FVa that retain the acidic region [14] , and that FV stimulates the inhibition of FXa by TFPIa [15] . To obtain more insights into the functional significance of the FV-TFPIa interaction, we investigated the effect of a peptide with the same amino acid sequence as the C-terminus of TFPIa (TFPIa C-term) on thrombin generation in plasma. By using a peptide instead of full-length TFPIa, we were able to isolate the effects arising from the FV-TFPIa interaction from the inhibition of the TFFVIIa complex and of FXa by the Kunitz domains of TFPIa.
TFPIa C-term had an overall anticoagulant action, prolonging the lag time and decreasing the peak height of thrombin generation in a dose-dependent manner. The . To minimize peptide carry-over, FV(a) was diluted 125 times from the activation mixture to the prothrombinase assay. FVa activity is expressed as nM thrombin FIIa min -1 formed in prothrombinase.
peptide was more effective at a low than at a high TF concentration, suggesting that its anticoagulant effect could be mediated by plasma TFPIa, which expresses anticoagulant activity particularly in the presence of low procoagulant stimuli [24] . Addition of neutralizing anti-TFPI antibodies that were directed against the Kunitz domains of TFPIa but not against its C-terminus, in order not to interfere with the peptide action, showed that the effect of the peptide was indeed less pronounced in the absence of TFPIa. When coagulation was initiated with FXa instead of TF, the peptide inhibited thrombin generation even more potently, localizing the effect downstream of FXa in the coagulation cascade. Finally, the peptide did not inhibit thrombin generation in FVdepleted plasma reconstituted with purified FVa, which lacks the acidic region. This indicated that the anticoagulant action of the peptide is mediated by an interaction with the acidic region of FV and further localized the inhibitory effect at the level of FV activation and/or prothrombinase activity.
As an effect of the C-terminus of TFPIa on prothrombinase activity had been reported earlier [14] , we focused on the possibility that the peptide could inhibit FV activation by blocking access to the Arg 1545 cleavage site, which is located next to the acidic region. To test this hypothesis, we followed the FXa-catalyzed and thrombincatalyzed activation of purified plasma FV in the presence of increasing concentrations of TFPIa C-term by subsampling in time to a prothrombinase assay. Inclusion of TFPIa C-term in the activation mixture inhibited both thrombin-catalyzed and FXa-catalyzed FV activation/activity in a dose-dependent manner. Although part of this ) was incubated with 2.5 nM thrombin (A) or 2.5 nM FXa (B) and 40 lM 10/90 DOPS/DOPC phospholipid vesicles in the absence and presence of 5 lM TFPIa C-term. Timed aliquots were subjected to SDS-PAGE on pre-cast 4-15% gradient polyacrylamide gels (Bio-Rad Laboratories, Veenendaal, the Netherlands) under non-reducing conditions, and analyzed by western blotting with a mAb directed against the FV light chain. Time points (in minutes) are indicated above the gel. FV fragments are defined by their respective amino acid residues. The lowest band in the time-course of FV activation by FXa is the product of the cleavage of the FVa light chain at Arg 1765 [6] . FVa activity was followed over time by subsampling to a prothrombinase mixture containing 300 pM FXa, 1 lM prothrombin, 40 lM 10/90 DOPS/DOPC phospholipid vesicles, 1 lM Pefabloc-TH, and 3 mM Ca
2+
. To minimize peptide carry-over, FV(a) was diluted 125 times from the activation mixture to the prothrombinase assay. FVa activity is expressed as nM thrombin (FIIa) min -1 formed in prothrombinase.
effect could be attributed to inhibition of prothrombinase complexes containing intermediates of FV activation that retain the acidic region, western blot analysis indicated that TFPIa C-term also interfered with the proteolysis of FV, specifically delaying cleavage of FV at Arg 1545 . Remarkably, a similar finding has been reported for FV-short in a recent abstract [25] . The two effects of the peptide are, in fact, synergistic, as inhibition of FV proteolysis at Arg 1545 prolongs the window of opportunity for prothrombinase inhibition by preventing the separation of the acidic region from the light chain of FVa.
Owing to the proximity of the acidic region to the Arg 1545 cleavage site, TFPIa C-term is likely to act by blocking the access to the Arg 1545 cleavage site of FV. This 'steric hindrance' mechanism is supported by the observation that TFPIa, which is much bulkier than the C-terminal peptide, inhibited FV activation by thrombin at a 100-fold lower concentration than the peptide (as also observed for prothrombinase inhibition [14] ). Moreover, the activation of FV-short, which has a higher affinity than FV for the TFPIa C-terminus, due to the absence of the basic region [16] , was more efficiently inhibited by the peptide.
The fact that inhibition of FV cleavage at Arg 1545 by TFPIa C-term could be replicated with full-length TFPIa suggests that this anticoagulant mechanism may play a physiologic role. The physiologic target of this anticoagulant mechanism is presently unclear, but it is unlikely to be intact full-length FV, whose plasma concentration (~25 nM) is 100-fold higher than the that of full-length TFPIa (~0.25 nM). A more likely candidate could be FVshort, whose plasma concentration (1-2 nM) is closer to that of TFPIa and whose affinity for TFPIa is at least 10-fold higher than that of normal FV [16] . In fact, although FV-short shows partial constitutive activity before proteolysis, our data show that TFPIa can delay its further activation by inhibiting cleavage at Arg 1545 . Other possible targets of this anticoagulant activity of TFPIa might be early intermediates of FV activation and platelet FV, which retain the acidic region and bind TFPIa with high affinity, and which have already been proposed to be inhibited by TFPIa in the prothrombinase [14, 23] . These FV species are either formed in small amounts during the initiation of coagulation (early FV activation intermediates) or released at the site of injury by activated platelets (platelet FV), which also locally release TFPIa. The TFPIa requirement for inhibition of cleavage at Arg 1545 in these low-abundance high-affinity targets might be lower than the supraphysiologic TFPIa concentration used in our experiments.
Taken together, our data point to a novel anticoagulant function of full-length TFPIa, namely the ability of its C-terminus to delay FV activation by inhibiting cleavage of FV at Arg 1545 . This cleavage is a crucial event that marks the definite transition from FV, an anticoagulant . FV(a) was diluted 100 times from the activation mixture to the prothrombinase assay. To correct for possible inhibition of the prothrombinase by the TFPIa carried over from the activation mixture, the buffer used to dilute the FV(a) subsamples taken from the activation mixture without TFPIa was supplemented with TFPIa, resulting in equal TFPIa carry-over to the prothrombinase mixture. FVa activity is expressed as nM thrombin FIIa min -1 formed in prothrombinase (average of triplicate experiments AE standard deviation). molecule that does not support prothrombinase activity and actually acts as a cofactor of TFPIa in FXa inhibition [15] , to FVa, a procoagulant species that binds to FXa with high affinity [10] , thereby supporting prothrombinase activity and protecting FXa from inhibition by TFPIa [15] . By delaying cleavage at Arg 1545 , TFPIa could therefore contribute to the downregulation of coagulation via several mechanisms. First, it would slow down (the generation of) prothrombinase activity, because FV activation intermediates cleaved only at Arg 709 and/or Arg 1018 have a high FXa requirement for prothrombinase complex formation [10] , and their prothrombinase activity is susceptible to inhibition by TFPIa [14] . Moreover, it would preserve the TFPI-cofactor activity of FV (which relies on the interaction between the TFPIa C-terminus and the acidic region of FV [15] ), thereby enhancing and prolonging the ability of TFPIa to inhibit FXa. A third potential effect of delayed cleavage at Arg 1545 would be the maintenance of the cofactor activity of FV for activated protein C (APC) in the inactivation of FVIIIa [26] . In fact, it has been reported that this anticoagulant activity of FV requires the C-terminal portion of the Bdomain and is lost upon cleavage at Arg 1545 [27] . Although the molecular basis of the APC-cofactor activity of FV is still largely unknown [28] , preliminary experiments from our laboratory suggest that TFPIa C-term may improve the APC-cofactor activity of FV in FVIIIa inactivation, as probed with the Immunochrom APC resistance test [29] , presumably via protection of the Arg 1545 cleavage site in FV (data not shown). In conclusion, we propose that the TFPIa C-terminus may act as a 'gatekeeper' of the Arg 1545 cleavage site in FV, which controls the transition of FV from an anticoagulant to a procoagulant cofactor. As FV is much more abundant than TFPIa in plasma, further studies are needed to assess the physiologic relevance and the molecular forms of FV that are targeted by this novel anticoagulant function of TFPIa. . FV(a) was diluted 100 times from the activation mixture to the prothrombinase assay. In (C) and (D), to correct for possible inhibition of the prothrombinase by the TFPIa carried over from the activation mixture, the buffer used to dilute the FV(a) subsamples taken from the activation mixture without TFPIa was supplemented with TFPIa, resulting in equal TFPIa carry-over to the prothrombinase mixture. As FV-short showed considerable constitutive activity before proteolysis, FVa activity was expressed as a percentage of the final plateau after correction for the FVa activity at t = 0. The curves in (A) and (B) are averages of triplicate experiments AE standard deviation.
